MBX
NASDAQ · Pharmaceuticals
Mbx Biosciences Inc
$27.82
-0.32 (-1.14%)
Financial Highlights (FY 2025)
Revenue
515.19M
Net Income
92.27M
Gross Margin
50.5%
Profit Margin
17.9%
Rev Growth
+6.8%
D/E Ratio
1.22
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 50.5% | 50.5% | 50.5% |
| Operating Margin | 25.0% | 25.6% | 25.0% |
| Profit Margin | 17.9% | 19.4% | 19.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 515.19M | 454.58M | 572.08M |
| Gross Profit | 260.29M | 229.66M | 289.03M |
| Operating Income | 128.62M | 116.28M | 142.92M |
| Net Income | 92.27M | 88.31M | 111.14M |
| Gross Margin | 50.5% | 50.5% | 50.5% |
| Operating Margin | 25.0% | 25.6% | 25.0% |
| Profit Margin | 17.9% | 19.4% | 19.4% |
| Rev Growth | +6.8% | +2.6% | +10.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 860.59M | 796.49M | 740.28M |
| Total Equity | 708.30M | 642.95M | 738.46M |
| D/E Ratio | 1.22 | 1.24 | 1.00 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 143.26M | 124.50M | 146.54M |
| Free Cash Flow | 88.64M | 54.29M | 70.53M |